Natural killer group 2A (NkG2A) is an inhibitory receptor found on natural killer (NK) cells and certain subsets of CD8+ T cells. It forms a heterodimer with CD94, binding to the non-classical MHC-I molecule HLA-E, which is overexpressed in many cancers. This interaction suppresses cytotoxic activity, allowing tumor immune evasion. Targeting NkG2A has emerged as a promising strategy in cancer immunotherapy, with monoclonal antibodies demonstrating enhanced antitumor effects when combined with PD-1/PD-L1 or EGFR inhibitors. Beyond therapeutics, NkG2A is also a valuable biomarker for immune profiling. Novel bispecific antibodies targeting NkG2A exhibit high specificity and stability, enabling applications in immunohistochemistry, Western blotting, and diagnostics, including crossing biological barriers like the blood-brain barrier.
Fig.1 Schematic of NkG2A signaling.1
Reference
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
